

On page 2, line 4, after "McGeer et al., Glia, 7:84-92 (1993)" Applicant has inserted "; Spleiss et al., J. Neurosci. Res., 59:16-28 (1998)"

On page 3, line 10, after "Lipton et al., Nature, 364:626-632 (1993))." Applicant has inserted "In addition, other studies have shown that the expression of two serine protease inhibitors is up-regulated in activated microglia and may play a role in brain inflammation (Thakker-Varia et al., Mol. Brain Res., 56:99-107 (1998)). One group has also reported a microglia gene product, human brain *mu* opioid receptor (MOR), that may play an anti-inflammatory role (Chao et al., J. Pharm. Exp. Therapeutics, 281:998-1004 (1997)). "

On page 81, Applicant has deleted lines 5-7 and inserted "Although the invention has been described with reference to the presently-preferred embodiments, it should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the claims."

In addition, please replace originally-filed page 101 with the attached substitute sheet 101, as the original page contains an error in the sequence listing. Specifically, the sequence identified as number 26 has an extra "c" residue (position 21) in the Sequence Listing originally filed. Accordingly, substitute sheet 101 contains the following changes for sequence 26: (1) the "c" residue at position 21 has been deleted; (2) in the <211> field, the "49" was changed to "48" to correct the total number of residues; and (3) below the <400> field, at the end of the sequence, the "49" was changed to "48".

Page 101 of the specification has been amended to correct an obvious error in the application. Specifically, the TOGA anchor primer in the originally-filed sequence listing was listed as: GAATTCAACTGGAAGCGGCCCGCAGGAAT₁₈VNN instead of: GAATTCAACTGGAAGCGGCCCGCAGGAAT₁₈VNN. As shown, the incorrect